Loading clinical trials...

COMPLETEDPhase 2NCT00234039

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine ...

Lead sponsor: SWOG Cancer Research Network•98 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

RECRUITINGPhase 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225 · Non-muscle Invasive Bladder Cancer

RECRUITINGPhase 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

NCT06770582 · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, and more

RECRUITINGPhase 1/2

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158 · Urothelial Carcinoma, Bladder Cancer

RECRUITINGPhase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 8, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment58

Start dateNov 2006

Last updatedJan 8, 2016

Condition

Bladder Cancer

Locations shown

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas

USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, California

Cancer Centers of Central Florida, PA

Leesburg, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2016Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Trial snapshot

Condition

Locations shown

For caregivers